Fulvestrant - Latest Advances

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 06, 2025

ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target.

Journal: bioRxiv : the preprint server for biology

Published: October 03, 2025

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

Journal: Journal of managed care & specialty pharmacy

Published: August 30, 2025

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Journal: Science translational medicine

Published: August 27, 2025

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 22, 2025

In vivo CRISPR screening links NFKB1 to endocrine resistance in ER⁺ breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2025

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 31, 2025

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations.

Journal: Nature reviews. Clinical oncology

Published: July 22, 2025

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 21, 2025

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study.

Journal: Frontiers in pharmacology

Published: July 21, 2025

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Journal: International journal of molecular sciences

Published: July 19, 2025

SALL1 is an orchestrator of uterine receptivity in part via titration of estrogen signaling.

Journal: Endocrinology

Published: July 18, 2025

Filters

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target.

ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target.

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

In vivo CRISPR screening links NFKB1 to endocrine resistance in ER⁺ breast cancer.

In vivo CRISPR screening links NFKB1 to endocrine resistance in ER⁺ breast cancer.

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations.

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations.

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study.

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study.

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

SALL1 is an orchestrator of uterine receptivity in part via titration of estrogen signaling.

SALL1 is an orchestrator of uterine receptivity in part via titration of estrogen signaling.